Neuphoria Therapeutics (NASDAQ:NEUP) Announces Earnings Results, Beats Estimates By $0.47 EPS

Neuphoria Therapeutics (NASDAQ:NEUP) announced its earnings results on Friday. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.47, FiscalAI reports.

Neuphoria Therapeutics Stock Down 7.1%

NEUP traded down $0.36 during midday trading on Friday, hitting $4.73. The company had a trading volume of 79,662 shares, compared to its average volume of 45,000. Neuphoria Therapeutics has a 52 week low of $3.64 and a 52 week high of $21.40. The company has a market capitalization of $25.49 million, a price-to-earnings ratio of -1.07 and a beta of 0.72. The stock’s 50 day moving average price is $4.72 and its 200 day moving average price is $4.38.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on NEUP. Zacks Research raised shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday, January 22nd. Finally, HC Wainwright downgraded shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $21.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in shares of Neuphoria Therapeutics by 33.3% during the fourth quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock valued at $67,000 after buying an additional 4,325 shares during the last quarter. Persistent Asset Partners Ltd grew its holdings in shares of Neuphoria Therapeutics by 173.1% during the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after buying an additional 8,495 shares during the last quarter. Commonwealth Equity Services LLC acquired a new position in shares of Neuphoria Therapeutics during the fourth quarter valued at about $43,000. XTX Topco Ltd acquired a new position in shares of Neuphoria Therapeutics during the fourth quarter valued at about $47,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Neuphoria Therapeutics during the fourth quarter valued at about $54,000. 15.90% of the stock is currently owned by institutional investors and hedge funds.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.